Pharmaceuticals news continually updated from thousands of sources around the net.
23 hrs ago | Seeking Alpha
Teva is trying to recover the Copaxone sales loss due to patent expiration by introducing an improved version of Copaxone 40mg. Teva revealed positive data from the phase 3 study of its drug reslizumab for the treatment of moderate to severe asthma.
Saturday | AmericanBankingNews.com
Raptor Pharmaceutical Corp. Director Raymond Anderson sold 10,000 shares of the stock in a transaction dated Wednesday, September 10th. The shares were sold at an average price of $10.81, for a total transaction of $108,100.00.
Saturday | Seeking Alpha
The FDA grants tentative approval for Mylan's emtricitabine and tenofovir disoproxil fumarate combination tablets co-packaged with nevirapine tablets for the treatment of patients with HIV-1. The product is cleared for use alone or in combination with other antiretrovirals for the treatment of HIV-1 infection in adults and pediatric patients at least 12 years old and weighing at least 38 kg.
Saturday | The China Post
Eastman Chemical Co. said Thursday it would pay US$1.7 billion in cash to take over Taminco Corp, the world's largest maker of alkylamines, crucial to the pharmaceutical industry and others.
One of the 25 largest companies in the United States with more than $100 billion in annual revenue, Cardinal Health has promoted 25-year company veteran Michael Kaufmann to the top finance seat, effective Nov. 11. He will replace Jeffrey Henderson, 49, who will be retiring next August. Kaufmann has been CEO of Cardinal's pharmaceutical segment since 2009.
The report provides detailed information on partnership and licensing transactions, M&As, equity/debt offerings, private equity, and venture financing registered in the pharmaceuticals industry in July 2013. The report portrays detailed comparative data on the number of deals and their value in the last six months, subdivided by deal types, various therapy areas, and geographies.
It is remarkable what very profitable drug companies-as they merge into fewer giant multinationals-continue to get away with by way of crony capitalism. Despite frequent exposure of misdeeds, the army of drug company lobbyists in Washington continues to gain political influence and rake in corporate welfare at the expense of taxpayers.
The logo of Bayer AG is pictured at the Bayer Healthcare subgroup production plant in Wuppertal February 24, 2014. German drug firm Bayer has clinched a $2.9 billion deal to take over Norwegian cancer drug maker Algeta after being tendered 92.17 percent of the shares in a cash offer, the companies said on Monday.
Achillion Pharmaceuticals major shareholder Ra Capital Management, Llc sold 1,704,362 shares of Achillion Pharmaceuticals stock on the open market in a transaction dated Thursday, September 11th. The stock was sold at an average price of $20,356.30, for a total transaction of $34,694,504,180.60.
Morgan & Morgan reminds investors that a class action lawsuit has been commenced in the United States District Court for the Northern District of California on behalf of purchasers of Impax Laboratories, Inc. securities between May 20, 2013 through July 28, 2014, inclusive . The class action alleges that the Company and certain of its officers and/or directors violated Sections 10 and 20 of the Securities Exchange Act of 1934.
McKesson EVP Paul C. Julian unloaded 74,667 shares of McKesson stock on the open market in a transaction that occurred on Wednesday, September 10th. The shares were sold at an average price of $196.76, for a total value of $14,691,478.92.
Recently the company launched two products; the first generic version of Upsher-Smith's Klor-Con and the Dexmedetomidine Hydrochloride injection. Its ANDA Glatiramer Acetate injection 40 mg/mL, the generic version of Teva's Copaxone 40 mg/mL, has also been accepted for filing by the FDA.
ISPE announced the results of its 2014 - 2015 International Board of Directors election, revealing a slate of strategic leaders who represent a variety of pharmaceutical industry sectors. The Board will be responsible for the governance and strategic direction of the Society and will assume their elected positions at the 2014 ISPE Annual Meeting, 12-15 October in Las Vegas, NV, USA.
Global biopharmaceutical manufacturers demand a high level of quality, service and consistency when it comes to the supplies they need to produce their products. In order to meet these demands, suppliers must commit the resources, facilities and expertise to deliver whatever is needed, when it is needed, with a guarantee of quality assurance.
GILD is quickly being pushed to make a bid for a major acquisition to demonstrate to shareholders and the competition that it will aggressively defend its markets. ABBV's buying spree in our view may force GILD to get a little more aggressive and seek later stage assets with broad synergistic potential with its own Oncology/Inflammation pipeline.
We would like to confirm in response to a number of questions received today that the European Public Health Alliance is withdrawing its support for the proposed Health for Citizen's Intergroup in the European Parliament. EPHA had been discussing support for an Intergroup as part of a coalition of non-governmental organisations and organisations representing economic operators, a new and exciting venture with the expectation of supporting the European Parliament in implementing a coherent approach to citizens' health.
Updated: Sat Sep 13, 2014 08:35 pm
Copyright © 2014 Topix LLC